AUSTEDO：薬剤分析・市場予測 (～2032年)

当レポートでは、世界の主要7カ国 (米国・ドイツ・フランス・イタリア・スペイン・英国・日本) におけるハンチントン病治療薬AUSTEDOの動向を調査し、当該薬剤の作用機序、規制上のマイルストーン、臨床試験の動向、上市済み薬および開発後期の新興治療薬の概要、市場規模の推移・予測、国別の詳細分析、特許動向、アナリストの見解などをまとめています。

目次

第1章 レポートイントロダクション

第2章 AUSTEDO：概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢：開発後期の新興治療薬

第4章 AUSTEDO市場の評価

• ハンチントン病におけるAUSTEDO：市場の展望
• 米国市場の分析

第5章 SWOT分析

第6章 アナリストの見解

第7章 付録

第8章 DelveInsightのサービス

第9章 免責事項

第10章 DelveInsightについて

第11章 レポート購入オプション

List of Tables

• Table 1: AUSTEDO , Clinical Trial Description, 2023
• Table 2: AUSTEDO : General Description
• Table 3: Competitive Landscape (Late -stage Emerging Therapies)
• Table 4: AUSTEDO Market Size in the United States, in USD million (2019-2032)

List of Figures

• Figure 1: AUSTEDO Market Size in the United States, USD million (2019-2032)

"AUSTEDO Drug Insight and Market Forecast - 2032" report provides comprehensive insights about AUSTEDO for Huntington's disease in the United States. A detailed picture of the AUSTEDO for Huntington's disease in the United States for the study period 2019-2032 is provided in this report along with a detailed description of the AUSTEDO for Huntington's disease. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the AUSTEDO market forecast, analysis for Huntington's disease in the United States, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Huntington's disease.

Drug Summary:

AUSTEDO (deutetrabenazine) is a deuterated form of a small molecule inhibitor of the vesicular monoamine 2 transporter, or VMAT2, that is designed to regulate the levels of a specific neurotransmitter, dopamine, in the brain. The drug has been granted orphan drug designation for the treatment of Huntington's disease by the US FDA.

It is indicated in adults for the treatment of:

• Chorea associated with Huntington's disease.
• Tardive dyskinesia

Dosage and Administration

The dose of AUSTEDO is determined individually for each patient based on reduction of chorea or tardive dyskinesia and tolerability. When first prescribed to patients who are not being switched from tetrabenazine (a related VMAT2 inhibitor), the recommended starting dose of AUSTEDO is 6 mg administered orally once daily for patients with Huntington's disease.

• The dose of AUSTEDO may be increased at weekly intervals in increments of 6 mg per day, up to the maximum recommended daily dosage of 48 mg.
• Administer total daily dosages of 12 mg or above in two divided doses.
• Administer AUSTEDO with food.
• AUSTEDO should be consumed whole. Do not chew, crush, or break tablets.

Mechanism of Action

The precise mechanism by which deutetrabenazine exerts its effects in the treatment of tardive dyskinesia and chorea in patients with Huntington's disease is unknown but is believed to be related to its effect as a reversible depletor of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals. The major circulating metabolites (a-dihydrotetrabenazine [HTBZ] and b-HTBZ) of deutetrabenazine are reversible inhibitors of VMAT2, resulting in decreased uptake of monoamines into synaptic vesicles and depletion of monoamine stores.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the AUSTEDO description, mechanism of action, dosage and administration, research and development activities in Huntington's disease.
• Elaborated details on AUSTEDO regulatory milestones and other development activities have been provided in this report.
• The report also highlights the AUSTEDO research and development activity in Huntington's disease in detail across the United States.
• The report also covers the patents information with expiry timeline around AUSTEDO (Deutetrabenazine).
• The report contains forecasted sales of AUSTEDO for Huntington's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Huntington's disease.
• The report also features the SWOT analysis with analyst views for AUSTEDO in Huntington's disease.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AUSTEDO Analytical Perspective by DelveInsight

• In-depth AUSTEDO Market Assessment

This report provides a detailed market assessment of AUSTEDO in Huntington's disease in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

• AUSTEDO Clinical Assessment

The report provides the clinical trials information of AUSTEDO in Huntington's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Huntington's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AUSTEDO dominance.
• Other emerging products for Huntington's disease are expected to give tough market competition to AUSTEDO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AUSTEDO in Huntington's disease.
• Our in-depth analysis of the forecasted sales data from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AUSTEDO in Huntington's disease.

Key Questions

• What is the product type, route of administration and mechanism of action of AUSTEDO (Deutetrabenazine)?
• What is the clinical trial status of the study related to AUSTEDO in Huntington's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AUSTEDO development?
• What are the key designations that have been granted to AUSTEDO for Huntington's disease?
• What is the forecasted market scenario of AUSTEDO for Huntington's disease?
• What are the forecasted sales of AUSTEDO in the United States?
• What are the other emerging products available in Huntington's disease and how are they giving competition to AUSTEDO for Huntington's disease?
• Which are the late-stage emerging therapies under development for the treatment of Huntington's disease?

Table of Contents

1 Report Introduction

2 AUSTEDO Overview

• 2.1 Product Detail
• 2.2 Clinical Development
  • 2.2.1 Clinical Studies
  • 2.2.2 Clinical Trials Information
• 2.3 Regulatory Milestones
• 2.4 Other Developmental Activities
• 2.5 Product Profile

3 Competitive Landscape (Late-stage Emerging Therapies) *

4 AUSTEDO Market Assessment

• 4.1 Market Outlook of AUSTEDO in Huntington's disease
• 4.2 US Market Analysis
  • 4.2.1 Market Size of AUSTEDO in the US for Huntington's disease

5 SWOT Analysis

6 Analysts' Views

7 Appendix

• 7.1 Bibliography
• 7.2 Report Methodology

8 DelveInsight Capabilities

9 Disclaimer

10 About DelveInsight

11 Report Purchase Options